| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 9.73 | 9.48 |
| Gross Profit | 7.33 | 6.67 |
| Pretax Income | -2.05 | -3.57 |
| Net Income | -2.05 | -3.17 |
| Diluted EPS | -0.65 | -1.01 |
- Net Income YoY
- +35.2%
Key highlights
- Quarterly revenue rose to $9.73 million, up from $9.48 million in the prior year period
- Net loss narrowed significantly to $2.05 million, a 35.2% improvement year-over-year
- Gross profit increased to $7.33 million for the quarter, compared to $6.67 million in Q3-25
- Diluted loss per share improved to $0.65 following a 1-for-20 reverse stock split in September 2026
- Annual revenue reached $37.06 million based on trailing twelve-month market data
How the Period Went
Cytosorbents Corp achieved a steady operational performance in the third quarter of 2026, with revenue climbing to $9.73 million from $9.48 million in the same period last year. This topline growth was accompanied by a notable improvement in the bottom line, as the company narrowed its net loss to $2.05 million, representing a 35.2% recovery from the $3.17 million loss reported in Q3 2025. The reduction in net loss was mirrored by an improvement in diluted earnings per share, which moved from a $1.01 loss to a $0.65 loss. This progress reflects a stabilizing operational environment despite broader fiscal challenges encountered earlier in the fiscal year.
Margins and Profitability
Profitability metrics showed resilience during the quarter, with gross profit rising to $7.33 million from $6.67 million year-over-year. This indicates a robust gross margin, suggesting efficient production and cost management of the company's core medical device products. While the quarterly results were positive, the company's nine-month performance was impacted by significant negative swings in foreign currency transaction gains and losses, contributing to a year-to-date net loss of $12.0 million. This volatility in currency exchange remains a critical factor for the company’s consolidated profitability, contrasting with the more stable operating results seen in the standalone third quarter.
Business Overview
Cytosorbents Corporation is a medical device leader specializing in blood purification technology. Its flagship product, CytoSorb, is an extracorporeal cytokine adsorber designed to reduce the excessive inflammation often referred to as a cytokine storm, which can lead to organ failure in critically ill or cardiac surgery patients. The company serves the global healthcare sector, specifically targeting intensive care units and operating rooms. By removing excess cytokines and toxins from the blood, the technology aims to stabilize patients and improve survival rates in high-acuity conditions such as sepsis, trauma, and complications arising from major surgical procedures.
Financial Context
In the broader market context, Cytosorbents operates within the healthcare medical device industry with a market capitalization of $17.55 million. The stock has experienced high volatility recently, as evidenced by a 23.12% single-day price surge to $5.565, which stands in contrast to a 26.19% decline over the past quarter. With a Relative Strength Index of 56.5, the stock is currently positioned in a neutral technical zone. The company's annual revenue of $37.06 million reflects an established market presence, though it continues to navigate the transition toward sustained profitability in a sector characterized by high regulatory and R&D requirements.
Down 25.2% since our story on 19 Nov: $5.57 when we broke it → $4.16 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 21 Oct | $5.35 |
|---|---|
| 22 Oct | $6.01 |
| 23 Oct | $5.27 |
| 26 Oct | $4.47 |
| 27 Oct | $4.85 |
| 28 Oct | $5.24 |
| 29 Oct | $4.40 |
| 30 Oct | $4.54 |
| 2 Nov | $4.12 |
| 3 Nov | $4.54 |
| 4 Nov | $4.56 |
| 5 Nov | $4.60 |
| 6 Nov | $4.80 |
| 9 Nov | $5.83 |
| 10 Nov | $5.80 |
| 11 Nov | $5.34 |
| 12 Nov | $5.37 |
| 13 Nov | $4.87 |
| 16 Nov | $4.85 |
| 17 Nov | $4.52 |
| 18 Nov | $5.57 |
| 19 Nov | $5.13 |
| 20 Nov | $4.16 |
Industry Landscape
- Increased demand for blood purification technologies in intensive care units as hospitals prioritize shorter recovery times
- Growing adoption of cytokine adsorption therapy in cardiac surgery to mitigate post-operative inflammatory complications
- Sector-wide pressure from fluctuating hospital capital budgets and procurement cycles
- Ongoing impact of global currency volatility on the international sales of US-based medical device exporters
- Consolidation trends among specialized healthcare firms seeking to expand their critical care portfolios
| Share price | $5.57 |
|---|---|
| Market cap | $18M |
| Revenue (annual) | $37M |
| 1-month price change | +12.20% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Cytosorbents Corporation announcing third quarter 2026 financial results.
Track Cytosorbents Corp live
Get the next Cytosorbents Corp SEC filing seconds after it lands.



